Fatigue Reduction Diet for Lymphoma Survivors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if a special Fatigue Reduction Diet can reduce fatigue and improve the quality of life for lymphoma survivors. Participants will receive personalized diet advice from registered dietitians via phone or video calls for three months. The study will compare this diet to a general health course to assess effectiveness. Suitable candidates are those experiencing persistent fatigue due to lymphoma and consuming fewer than 5.5 servings of fruits and vegetables daily. As an unphased trial, it provides a unique opportunity to explore personalized dietary strategies to enhance well-being.
Will I have to stop taking my current medications?
The trial requires that you do not change your current medications, supplements, or therapies during the study. If you have recently started, stopped, or changed any chronic medications, you may not be eligible to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that the Fatigue Reduction Diet (FRD) is safe for people. An earlier study found that participants not only found the FRD easy to follow and enjoyable, but it also appeared to improve diet quality and reduce tiredness in lymphoma survivors. Participants reported feeling significantly less tired and experiencing less overall disability. This indicates that the diet is manageable and does not cause harmful side effects. Therefore, the evidence supports the safety of the FRD for those considering joining the trial.12345
Why are researchers excited about this trial?
Fatigue Reduction Diet (FRD) is unique because it offers a personalized nutritional approach to combat fatigue in lymphoma survivors, unlike standard treatments that mainly focus on medication and physical therapy. Researchers are excited about this diet because it involves individualized counseling from registered dietitians, providing tailored advice over the course of eight sessions via phone or video. This method aims to improve not only fatigue but also overall quality of life and associated symptoms, offering a holistic and accessible alternative to traditional treatment.
What evidence suggests that the Fatigue Reduction Diet could be effective for reducing fatigue in lymphoma survivors?
Research has shown that the Fatigue Reduction Diet (FRD), which participants in this trial may receive, can help lymphoma survivors experiencing ongoing tiredness. In earlier studies, individuals who followed the FRD felt significantly less tired and reported an improved quality of life. The diet not only reduced their fatigue but also increased their confidence in managing it. Additionally, participants found the FRD easy to follow. This suggests that dietary changes can be a powerful way to manage fatigue for lymphoma survivors.14678
Who Is on the Research Team?
Suzie Zick
Principal Investigator
University of Michigan Rogel Cancer Center
Are You a Good Fit for This Trial?
This trial is for men and women over 18 who finished their primary lymphoma treatments between 6 months to 2 years ago, have no signs of disease getting worse, eat less than 5.5 servings of fruits and veggies a day, were treated with specific chemo regimens (R-CHOP or R-EPOCH), suffer from persistent fatigue since their diagnosis, and can use email for study questionnaires.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
3 months of individualized counseling of the Fatigue Reduction Diet (FRD) or General Health Curriculum (GHC) delivered by registered dietitians over 8 sessions by phone/video conferencing
Follow-up
Participants are monitored for improvements in fatigue, quality of life, and associated symptoms, maintained at 15-months post-enrollment
What Are the Treatments Tested in This Trial?
Interventions
- Fatigue Reduction Diet
- General Health Curriculum
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan Rogel Cancer Center
Lead Sponsor
American Institute for Cancer Research
Collaborator